Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

They also point to lebrikizumab’s safety profile, including low rates of conjunctivitis, which is a known side effect of Dupixent. In trials, Ebglyss showed good and durable efficacy ...

including a low rate of conjunctivitis, which is a recognised side effect with Dupixent. The drug has also been approved in the EU, although it was turned down by the FDA in the US, where rights ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...